
位置: Boston
日期:
活動詳細資訊: The Redefining Early Stage Investments (RESI) conference series connects start-ups and early-stage investors and strategic channel partners across the lifescience and healthcare industry. Australia is a preferred destination for early phase trials because of simple and fast regulatory stream and lucrative R&D cash refund scheme. Our Novotech clinical team have almost 20 years’ experience working on 500+ early phase studies, making us an exceptionally experienced local provider within the Australian & New Zealand market and a partner of choice for many international biotech companies. Dates for RESI : June 5 in person | June 6-7 virtual
預約會面
與會者
John Moller
Barry Murphy
Andy Liu
Plus team members from our Novotech China, Novotech DDC and US BD teams